Repetitive transcranial magnetic stimulation (rTMS) of the brain may be considered medically necessary as a treatment of major depressive disorder when ALL of the following conditions have been met:

• Confirmed diagnosis of severe major depressive disorder (single or recurrent) documented by standardized rating scales that reliably measure depressive symptoms; and
• ANY ONE of the following:
  • Failure of 4 trials of psychopharmacologic agents including 2 different agent classes and 2 augmentation trials; or
  • Inability to tolerate a therapeutic dose of medications as evidenced by 4 trials of psychopharmacologic agents with distinct side effects; or
  • History of response to rTMS in a previous depressive episode (at least 3 months since the prior episode); or
  • Is a candidate for electroconvulsive therapy (ECT) and ECT would not be clinically superior to rTMS (e.g., in cases with psychosis, acute suicidal risk, catatonia or life-threatening inanition rTMS should NOT be utilized);

AND

• Failure of a trial of a psychotherapy known to be effective in the treatment of major depressive disorder of an adequate frequency and duration, without significant improvement in depressive symptoms, as documented by standardized rating scales that reliably measure depressive symptoms; and
• None of the following conditions are present:
  • Seizure disorder or any history of seizure with increased risk of future seizure; or
  • Presence of acute or chronic psychotic symptoms or disorders (such as schizophrenia, schizophreniform or schizoaffective disorder) in the current depressive episode; or
  • Neurologic conditions that include epilepsy, cerebrovascular disease, dementia, increased intracranial pressure, having a history of repetitive or severe head trauma, or with primary or secondary tumors in the central nervous system (CNS); or
  • Presence of an implanted magnetic-sensitive medical device located 30 centimeters or less from the TMS magnetic coil or other implanted metal items, including but not limited to a cochlear implant, implanted cardioverter defibrillator (ICD), pacemaker, vagus nerve stimulator, or metal aneurysm clips or coils, staples, or stents.

rTMS should be performed using an FDA-cleared device in appropriately selected patients, by physicians who are adequately trained and experienced in the specific techniques used. A treatment course should not exceed 5 days a week for 6 weeks (total of 30 sessions), followed by a 3-week taper of 3 TMS treatments in week 1, 2 TMS treatments the next week, and 1 TMS treatment in the last week.

All of the following should be present for the administration of rTMS and documented in the medical record and available upon request:

• An attendant trained in basic cardiac life support and the management of complications such as seizures, as well as the use of the equipment must be present at all times; and
• Adequate resuscitation equipment including, for example, suction and oxygen; and
• The facility must maintain awareness of response times of emergency services (either fire/ambulance or “code team”), which should be available within five minutes. These relationships are reviewed on at least a one year basis and include mock drills.

rTMS for major depressive disorder that does not meet the criteria listed above is considered experimental/investigational and therefore, not covered. A participating, preferred, or network provider can bill the member for the non-covered service.

Continued treatment with rTMS of the brain as maintenance therapy is considered experimental/investigational and therefore, not covered. A participating, preferred, or network provider can bill the member for the non-covered service.

Transcranial magnetic stimulation of the brain is considered experimental/investigational and therefore not covered for any other indication. There is insufficient evidence in medical literature to support the effectiveness of this procedure.  A participating, preferred, or network provider can bill the member for the denied service.

Place of Service: Outpatient

TMS is typically an outpatient procedure which is only eligible for coverage as an inpatient procedure in special circumstances including, but not limited to the presence of a co-morbid condition that would require monitoring in a more controlled environment such as the inpatient setting.

Description

Transcranial magnetic stimulation (TMS) is a method of  noninvasive stimulation of the brain through a small coil placed over the scalp. A rapidly alternating current is then passed through the coil wire, producing a magnetic field that passes unimpeded through the scalp and bone, resulting in electrical stimulation of the cortex. TMS was initially used to investigate nerve conduction. For example, TMS over the motor cortex will produce a contralateral muscular-evoked potential. This “motor threshold” (MT), which is the minimum intensity of stimulation required to induce a motor response, is empirically determined for each individual by gradually increasing the intensity of stimulation. TMS has been investigated as a treatment for major depressive disorders that are resistant to treatment. It is also being tested as a treatment for other disorders including, but not limited to, schizophrenia, obsessive-compulsive disorder, and bulimia.

NOTE:

This policy is designed to address medical guidelines that are appropriate for the majority of individuals with a particular disease, illness, or condition. Each person's unique clinical circumstances may warrant individual consideration, based on review of applicable medical records.

This medical policy may not apply to FEP. Medical policy is not an authorization, certification, explanation of benefits, or a contract. Benefits are determined by the Federal Employee Program.

02/2011, Transcranial magnetic stimulation considered investigational
10/2014, Transcranial magnetic stimulation considered medically necessary
10/2014, Place of service designation included on additional medical policies

O’Reardon J, Solvason H, Janicak P, et. al. Efficacy and Safety of Transcranial Magnetic Stimulation in the Acute Treatment of Major Depression: A Multisite Randomized Controlled Trial. Biol Psychiatry. 2007;62:1208-1216.

Avery D, Isenberg K, Sampson S. Transcranial Magnetic Stimulation in the Acute Treatment of Major Depressive Disorder: Clinical Response in an Open-Label Extension Trial. J Clin Psychiatry. March 2008;69(3):441-451.

Lisanby S, Husain M, Rosenquist P, et al. Daily Left Prefrontal Repetitive Transcranial Magnetic Stimulation in the Acute Treatment of Major Depression: Clinical Predictors of Outcome in a Multisite, Randomized Controlled Clinical Trial. Neuropsychopharmacology. 2009;34:522-534.

Demitrack M, Thase M. Clinical Significance of Transcranial Magnetic Stimulation (TMS) in the Treatment of Pharmacoresistant depression: Synthesis of Recent Data. Psychopharmacology Bulletin. 2009;42(2):5-38.

National Guideline Clearinghouse. Depression. The treatment and management of depression in adults.

Tice J, Feldman M. Repetitive Transcranial Magnetic Stimulation for Treatment Resistant Depression. California Technology Assessment Forum. June 17, 2009.

George M, Lisanby S, Avery D. Daily Left Prefrontal Transcranial Magnetic Stimulation Therapy for Major Depressive Disorder. Arch Gen Psychiatry. 2010;67(5):507-516.

Slotema C, Blom J, Hoek H, Sommer I. Should We Expand the Toolbox of Psychiatric Treatment Methods to Include Repetitive Transcranial Magnetic Stimulation (rTMS)?  A Meta-analysis of the Efficacy of rTMS in Psychiatric Disorders. J Clin Psychiatry. 2010;E1-E13.

Janicak P, Nahas Z, Lisanby. Durability of clinical benefit with transcranial magnetic stimulation (TMS) in the treatment of pharmacoresistant major depressions assessment of relapse during a 6-month, multisite, open-label study. Brain Stimulation. August 2010.

Gelenberg A, Freeman M, Marlowitz J, et al. Practice Guideline for the Treatment of Patients with Major Depressive Disorder. Am J Psych Supp. October 2010;167(10):1-152.

American Psychiatric Association. Practice Guideline for the Treatment of Patients with Major Depressive Disorder. Third Edition: American Psychiatric Publishing; 2010, http://psychiatryonline.org/content.aspx?bookid=28&sectionid=1667485. Accessed August 11, 2014.

Carpenter LL, Janicak PG, Aaronson ST, et al. Transcranial magnetic stimulation (tms) for major depression: a multisite, naturalistic, observational study of acute treatment outcomes in clinical practice. Depress Anxiety. 2012 Jun 11. doi:10.1002/da.21969. [Epub ahead of print]

Balconi M, Ferrari C. rTMS stimulation on left dlpfc affects emotional cue retrieval as a function of anxiety level and gender. Depress Anxiety. 2012 Jun 11. doi:10.1002/da.21968. [Epub ahead of print]

Mantovani A, Pavlicova M, Avery D, et al. Long-term efficacy of repeated daily prefrontal transcranial magnetic stimulation (tms) in treatmnt-resistant depression. Depress Anxiety. 2012 Jun 11. doi:10.1002/da.21967. [Epub ahead of print]

Kreuzer PM, Landgrebe M, Frank E, Langguth B. Repetitive Transcranial Magnetic Stimulation for the Treatment of Chronic Tinnitus After Traumatic Brain Injury: A Case Study. J Head Trauma Rehabil. 2012 Jun 8. [Epub ahead of print]

Schulz R, Gerloff C, Hummel FC. Non-invasive brain stimulation in neurological diseases. Neuropharmacology. 2012 Jun 8. [Epub ahead of print]

Fitzgerald PB, Grace N, Hoy KE, Bailey M, Daskalakis ZJ. An open label trial of clustered maintenance rTMS for patients with refractory depression. Brain Stimul. 2012 Jun 1. [Epub ahead of print]

Lee JC, Blumberger DM, Fitzgerald P, Daskalakis Z, Levinson A. The Role of Transcranial Magnetic Stimulation in Treatment-Resistant Depression: A Review. Curr Pharm Des. 2012 Jun 6. [Epub ahead of print]

Guse B, Falkai P, Wobrock T. Cognitive effects of high-frequency repetitive transcranial magnetic stimulation: A systematic review. J Neural Transm. 2010;117(1):105-122.

Kranz G, Shamim EA, Lin PT, et al. Transcranial magnetic brain stimulation modulates blepharospasm: A randomized controlled study. Neurology. 2010;75(16):1465-1471.

Blue Cross and Blue Shield Association Technology Evaluation Center (TEC). Transcranial magnetic stimulation for depression. TEC Assessments 2011;26(5):1-28.

Rossi S, Hallett M, Rossini PM, Pascual-Leone A. Safety of TMS Consensus Group. Safety, ethical considerations, and application guidelines for the use of transcranial magnetic stimulation in clinical practice and research. Clin Neurophysiol. 2009;120(12):2008-2039.

Carpenter LL, Janicak PG, Aaronson ST, et al. Transcranial magnetic stimulation (TMS) for major depression: A multisite, naturalistic, observational study of acute treatment outcomes in clinical practice. Depression and Anxiety. 2012;29:587-596.

Janicak PG, Dunner DL, Aaronson ST, et al. Transcranial magnetic stimulation (TMS) for major depression: A multisite, naturalistic, observational study of quality of life outcome measure in clinical practice. CNS Spectrums. 2013;18(6);322-332. doi: 10.1017/S1092852913000357

Ullrich H, Kranaster L, Sigges E, et al. Ultra-high-frequency left prefrontal transcranial magnetic stimulation as augmentation in severely ill patients with depression: a naturalistic sham-controlled, double-blind, randomized trial. Neuropsychobiology. 2012;66(3):141-148.

Berlim MT, Van den Eynde F, Jeff Daskalakis Z. Clinically meaningful efficacy and acceptability of low-frequency repetitive transcranial magnetic stimulation (rTMS) for treating primary major depression: A meta-analysis of randomized, double-blind and sham-controlled trials. Neuropsychopharmacology. 2013;38(4):543-551.

Gaynes B, Lux L, Lloyd S, et al. Nonpharmacologic interventions for treatment-resistant depression in adults. comparative effectiveness review No. 33. (Prepared by RTI International-University of North Carolina (RTI-UNC) Evidence based Practice Center under Contract No. 290-02-0016I.) AHRQ Publication No. 11-EHC056- EF. Rockville, MD: Agency for Healthcare Research and Quality. 2011. http://www.effectivehealthcare.ahrq.gov/ehc/products/76/792/TRD_CER33_20111110.pdf. Accessed July 25, 2014.